文献速递膀胱癌与上尿路尿路上皮癌

老年膀胱癌高精度放疗:基于碘油标记图像引导的当日计划整合推量技术临床结果

High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers.
PubMed 文献 · Eur Urol Oncol · 2018-09-07

本研究纳入44例局部单发T2-T4N0M0级2-3肌层浸润性膀胱癌老年患者(中位年龄80岁),采用碘油标记联合当日计划整合推量技术(LPOD)靶向放疗。中位随访38个月,局部复发率11.4%,3年尿路上皮癌特异性生存率77%,3年总生存率49%,RTOG>3级毒性2.3-12.9%。作者认为LPOD是老年局限体积肌层浸润性膀胱癌可行的first-line治疗选择。

要点

  • LPOD靶向放疗局部复发率11.4%,3年尿路上皮癌特异性生存率77%。
  • 3年总生存率49%,RTOG>3级毒性2.3-12.9%。
  • 作者认为LPOD是老年局限体积T2-T4N0M0级2-3肌层浸润性膀胱癌可行的first-line治疗选择。

核心结论

  • LPOD是老年局限体积T2-T4N0M0级2-3肌层浸润性膀胱癌可行的first-line治疗选择。

研究设计与样本

  • 2008年9月至2016年9月在本院筛查所有肌层浸润性膀胱癌患者,纳入局部单发T2-T4N0M0级2-3患者,共44例,中位年龄80岁。
  • 排除肿瘤体积超过膀胱壁表面50%、既往盆腔放疗、单侧或双侧髋关节假体患者。
  • 采用碘油标记联合当日计划整合推量技术(LPOD)靶向放疗。
  • 统计分析包括独立样本t检验、χ2检验和Mann-Whitney U检验。

主要发现

  • 中位随访38个月,1例停止治疗,23例死亡。
  • LPOD导致局部复发概率11.4%。
  • 3年尿路上皮癌特异性生存率77%。
  • RTOG>3级毒性为2.3-12.9%。
  • 3年总生存率49%。

临床怎么用

  • 作者认为LPOD是老年局限体积T2-T4N0M0级2-3肌层浸润性膀胱癌可行的first-line治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For most elderly patients with muscle-invasive bladder cancer (MIBC), surgery is not an option because of patient frailty. Conventional radiotherapy, with its high-dose irradiation of surrounding healthy tissues, remains the only curative treatment for this patient population. OBJECTIVE: To determine whether targeted radiotherapy with Lipiodol demarcation and plan-of-the-day integrated boost technique (LPOD) is a viable curative treatment for elderly patients with MIBC. DESIGN, SETTING, AND PARTICIPANTS: Between September 2008 and September 2016 all MIBC patients in our hospital were screened for eligibility. We included patients with localised, unifocal T2-T4N0M0 grade 2-3 MIBC. Patients with a tumour volume >50% of the bladder wall surface, previous pelvic radiotherapy, and unilateral or bilateral hip prostheses were excluded. INTERVENTION: Targeted radiotherapy using LPOD. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival, urothelial cell cancer-specific survival (UCCSS), disease recurrence, and Radiation Therapy Oncology Group (RTOG) toxicity were measured. Statistical analyses included independent-sample t tests, χ2 tests, and Mann-Whitney U tests. RESULTS AND LIMITATIONS: A total of 44 patients (median age 80 yr) were included. Over median follow-up of 38 mo, one patient ceased treatment and 23 patients died. LPOD resulted in a 11.4% chance of local recurrence, high 3-yr UCCSS of 77%, RTOG grade >3 toxicity of 2.3-12.9%, and 3-yr overall survival of 49%. CONCLUSIONS: LPOD is a feasible first-line treatment option for older patients with limited-volume T2-T4N0M0 grade 2-3 MIBC. PATIENT SUMMARY: We looked at outcomes after targeted radiotherapy in elderly patients with muscle-invasive bladder cancer. We found that this treatment results in a low chance of disease recurrence with few toxicity complaints. We conclude that this treatment is a viable first-line treatment option for elderly patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Beulens AJW, van der Toorn PP, de Wildt MJ, et al. High-precision Bladder Cancer Irradiation in the Elderly: Clinical Results for a Plan-of-the-day Integrated Boost Technique with Image Guidance Using Lipiodol Markers. Eur Urol Oncol. 2018. PMID: 30929845. doi:10.1016/j.euo.2018.08.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。